BIOLASE, Inc. (NASDAQ: BIOL), the world's leading manufacturer and distributor of dental lasers, and a pioneer in laser surgery in other medical specialties, today announced that its Board of Directors has declared a one-half percent stock dividend payable on September 13, 2013, to stockholders of record on August 30, 2013.
Cardiovascular Systems, Inc. (CSII)
DexCom, Inc. (DXCM) today reported its unaudited financial results as of and for the quarter ended June 30, 2013.
Product revenue grew to $35.5 million for the second quarter of 2013, an increase of approximately 65% from the $21.5 million in product revenue reported for the second quarter of 2012. Total second quarter 2013 revenue, which included development grant and other revenue, grew to $35.8 million, an increase of 53% from the same quarter in 2012. Product gross profit totaled $21.8 million for the three months ended June 30, 2013, compared to a product gross profit of $10.6 million for the three months ended June 30, 2012.
Dynatronics Corporation (DYNT) today announced the introduction of the new 25 Series electrotherapy/ultrasound therapy product line. This new line consists of four separate devices: the Dynatron 925, Dynatron 825, Dynatron 625 and Dynatron 525.
These four units provide seven different types of electrotherapy treatments and three frequencies of ultrasound, including Dynatronics' proprietary three-frequency ultrasound transducers. They are capable of delivering between three and five separate treatments simultaneously, depending on the model. The ability to provide multiple treatments simultaneously is expected to be very helpful in busy clinics and training rooms, or for patients needing treatment of multiple areas of the body.
Total Sales of $18.2 Million Increased 14% from Q2 2012 / 20% Increase on Constant Currency Basis
Visian® ICL™ Sales Grew 31% to Record $11.3 Million
Visian ICL with CentraFLOW™ Technology Continues to Drive Growth
Company Increases Revenue Growth Metric for the Year
GAAP Net Income of $0.01 per share; Non-GAAP Adjusted Net Income of $0.05 per share
STAAR Surgical Company (STAA), a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today reported revenue for the second quarter ended June 28, 2013 of $18.2 million, which represented 14% growth compared to $15.9 million reported for the second quarter of 2012.
